{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:56:28Z","timestamp":1780775788110,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["SAF2010-18277"],"award-info":[{"award-number":["SAF2010-18277"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS14\/00099"],"award-info":[{"award-number":["FIS14\/00099"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CPII16\/00011"],"award-info":[{"award-number":["CPII16\/00011"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010789","name":"Direcci\u00f3n General de Universidades e Investigaci\u00f3n","doi-asserted-by":"publisher","award":["AICO\/2018\/090"],"award-info":[{"award-number":["AICO\/2018\/090"]}],"id":[{"id":"10.13039\/501100010789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The disintegrin metalloproteinase 10 (ADAM10) is the main \u03b1-secretase acting in the non-amyloidogenic processing of APP. Some <jats:italic>ADAM10<\/jats:italic> gene variants have been associated with higher susceptibility to develop late-onset AD, though clear clinical-genetic correlates remain elusive.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinical-genetic and biomarker study of a first family with early- and late-onset AD associated with a nonsense <jats:italic>ADAM10<\/jats:italic> mutation (p.Tyr167*). CSF analysis included AD core biomarkers, as well as Western blot of ADAM10 species and sAPP\u03b1 and sAPP\u03b2 peptides. We evaluate variant\u2019s pathogenicity, pattern of segregation, and further screened for the p.Tyr167* mutation in 197 familial AD cases from the same cohort, 200 controls from the same background, and 274\u2009AD cases from an independent Spanish cohort.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mutation was absent from public databases and segregated with the disease. CSF A\u03b242, total tau, and phosphorylated tau of affected siblings were consistent with AD. The predicted haploinsufficiency effect of the nonsense mutation was supported by (a) ADAM10 isoforms in CSF decreased around 50% and (b) 70% reduction of CSF sAPP\u03b1 peptide, both compared to controls, while sAPP\u03b2 levels remained unchanged. Interestingly, sporadic AD cases had a similar decrease in CSF ADAM10 levels to that of mutants, though their sAPP\u03b1 and sAPP\u03b2 levels resembled those of controls. Therefore, a decreased sAPP\u03b1\/sAPP\u03b2 ratio was an exclusive feature of mutant <jats:italic>ADAM10<\/jats:italic> siblings. The p.Tyr167* mutation was not found in any of the other AD cases or controls screened.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This family illustrates the role of <jats:italic>ADAM10<\/jats:italic> in the amyloidogenic process and the clinical development of the disease. Similarities between clinical and biomarker findings suggest that this family could represent a genetic model for sporadic late-onset AD due to age-related downregulation of \u03b1-secretase. This report encourages future research on ADAM10 enhancers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-020-00708-0","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T16:02:48Z","timestamp":1604160168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["\u03b1-Secretase nonsense mutation (ADAM10 Tyr167*) in familial Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"12","author":[{"given":"Pablo","family":"Ag\u00fcero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Sainz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Salud","family":"Garc\u00eda-Ayll\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"S\u00e1ez-Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"T\u00e9llez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Guerrero-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"P\u00e9rez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Jim\u00e9nez-Escrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5665-3487","authenticated-orcid":false,"given":"Estrella","family":"G\u00f3mez-Tortosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,31]]},"reference":[{"key":"708_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1385\/JMN:23:3:157","volume":"23","author":"JW Ashford","year":"2004","unstructured":"Ashford JW. APOE genotype effects on Alzheimer\u2019s disease onset and epidemiology. J Mol Neurosci. 2004;23:157\u201365. \n                  https:\/\/doi.org\/10.1385\/JMN:23:3:157\n                  \n                .","journal-title":"J Mol Neurosci"},{"issue":"2","key":"708_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00401-019-02004-0","volume":"138","author":"P Dourlen","year":"2019","unstructured":"Dourlen P, Kilinc D, Malmanche N, et al. The new genetic landscape of Alzheimer\u2019s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? Acta Neuropathol. 2019;138(2):221\u201336. \n                  https:\/\/doi.org\/10.1007\/s00401-019-02004-0\n                  \n                .","journal-title":"Acta Neuropathol"},{"key":"708_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297:353\u20136. \n                  https:\/\/doi.org\/10.1126\/science.1072994\n                  \n                .","journal-title":"Science."},{"key":"708_CR4","doi-asserted-by":"publisher","first-page":"a006270","DOI":"10.1101\/cshperspect.a006270","volume":"2","author":"C Haass","year":"2012","unstructured":"Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med. 2012;2:a006270. \n                  https:\/\/doi.org\/10.1101\/cshperspect.a006270\n                  \n                .","journal-title":"Cold Spring Harb Perspect Med"},{"key":"708_CR5","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1073\/pnas.96.7.3922","volume":"96","author":"S Lammich","year":"1999","unstructured":"Lammich S, Kojro E, Postina R, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer\u2019s amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A. 1999;96:3922\u20137. \n                  https:\/\/doi.org\/10.1073\/pnas.96.7.3922\n                  \n                .","journal-title":"Proc Natl Acad Sci U S A"},{"key":"708_CR6","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1038\/emboj.2010.167","volume":"29","author":"PH Kuhn","year":"2010","unstructured":"Kuhn PH, Wang H, Dislich B, et al. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J. 2010;29:3020\u201332. \n                  https:\/\/doi.org\/10.1038\/emboj.2010.167\n                  \n                .","journal-title":"EMBO J"},{"issue":"1","key":"708_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/ph11010012","volume":"11","author":"R Peron","year":"2018","unstructured":"Peron R, Vatanabe IR, Manzine PR, et al. Alpha-secretase ADAM10 regulation: insights into Alzheimer\u2019s disease treatment. Pharmaceuticals (Basel). 2018;11(1):12. \n                  https:\/\/doi.org\/10.3390\/ph11010012\n                  \n                .","journal-title":"Pharmaceuticals (Basel)"},{"key":"708_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejphar.2017.06.018","volume":"817","author":"S Musardo","year":"2017","unstructured":"Musardo S, Marcello E. Synaptic dysfunction in Alzheimer\u2019s disease: from the role of amyloid \u03b2-peptide to the \u03b1-secretase ADAM10. Eur J Pharmacol. 2017;817:30\u20137. \n                  https:\/\/doi.org\/10.1016\/j.ejphar.2017.06.018\n                  \n                .","journal-title":"Eur J Pharmacol"},{"key":"708_CR9","doi-asserted-by":"publisher","first-page":"108661","DOI":"10.1016\/j.biopha.2019.108661","volume":"113","author":"PR Manzine","year":"2019","unstructured":"Manzine PR, Ettcheto M, Cano A, et al. ADAM10 in Alzheimer\u2019s disease: pharmacological modulation by natural compounds and its role as a peripheral marker. Biomed Pharmacother. 2019;113:108661. \n                  https:\/\/doi.org\/10.1016\/j.biopha.2019.108661\n                  \n                .","journal-title":"Biomed Pharmacother"},{"key":"708_CR10","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1172\/JCI20864","volume":"113","author":"R Postina","year":"2004","unstructured":"Postina R, Schroeder A, Dewachter I, et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest. 2004;113:1456\u201364. \n                  https:\/\/doi.org\/10.1172\/JCI20864\n                  \n                .","journal-title":"J Clin Invest"},{"key":"708_CR11","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing. Nat Genet. 2019;51:414\u201330. \n                  https:\/\/doi.org\/10.1038\/s41588-019-0358-2\n                  \n                .","journal-title":"Nat Genet"},{"key":"708_CR12","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1093\/hmg\/ddp323","volume":"18","author":"M Kim","year":"2009","unstructured":"Kim M, Suh J, Romano D, et al. Potential late-onset Alzheimer\u2019s disease-associated mutations in the ADAM10 gene attenuate alpha-secretase activity. Hum Mol Genet. 2009;18:3987\u201396. \n                  https:\/\/doi.org\/10.1093\/hmg\/ddp323\n                  \n                .","journal-title":"Hum Mol Genet"},{"key":"708_CR13","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1212\/01.wnl.0000187068.92184.63","volume":"65","author":"JS Goldman","year":"2005","unstructured":"Goldman JS, Farmer JM, Wood EM, et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology. 2005;65:1817\u20139. \n                  https:\/\/doi.org\/10.1212\/01.wnl.0000187068.92184.63\n                  \n                .","journal-title":"Neurology."},{"key":"708_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3233\/JAD-159006","volume":"48","author":"P Lewczuk","year":"2015","unstructured":"Lewczuk P, Kornhuber J, Toledo JB, et al. Validation of the Erlangen score algorithm for the prediction of the development of dementia due to Alzheimer\u2019s disease in pre-dementia subjects. J Alz Dis. 2015;48:433\u201341. \n                  https:\/\/doi.org\/10.3233\/JAD-159006\n                  \n                .","journal-title":"J Alz Dis"},{"issue":"1","key":"708_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12974-018-1255-9","volume":"15","author":"A Sogorb-Esteve","year":"2018","unstructured":"Sogorb-Esteve A, Garc\u00eda-Ayll\u00f3n MS, Gobom J, et al. Levels of ADAM10 are reduced in Alzheimer\u2019s disease CSF. J Neuroinflammation. 2018;15(1):213. \n                  https:\/\/doi.org\/10.1186\/s12974-018-1255-9\n                  \n                .","journal-title":"J Neuroinflammation"},{"issue":"10","key":"708_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1750-1326-10-2","volume":"8","author":"I Cuchillo-Iba\u00f1ez","year":"2015","unstructured":"Cuchillo-Iba\u00f1ez I, Lopez-Font I, Boix-Amor\u00f3s A, et al. Heteromers of amyloid precursor protein in cerebrospinal fluid. Mol Neurodegener. 2015;8(10):2. \n                  https:\/\/doi.org\/10.1186\/1750-1326-10-2\n                  \n                .","journal-title":"Mol Neurodegener"},{"issue":"4","key":"708_CR17","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3233\/JAD-161275","volume":"57","author":"I Lopez-Font","year":"2017","unstructured":"Lopez-Font I, Boix CP, Zetterberg H, et al. Alterations in the balance of amyloid-\u03b2 protein precursor species in the cerebrospinal fluid of Alzheimer\u2019s disease patients. J Alzheimers Dis. 2017;57(4):1281\u201391. \n                  https:\/\/doi.org\/10.3233\/JAD-161275\n                  \n                .","journal-title":"J Alzheimers Dis"},{"key":"708_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324. \n                  https:\/\/doi.org\/10.1038\/gim.2015.30\n                  \n                .","journal-title":"Genet Med"},{"issue":"4","key":"708_CR19","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: towards a biological definition of Alzheimer\u2019s disease. Alzheimer Dement. 2018;14(4):535\u201362. \n                  https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018\n                  \n                .","journal-title":"Alzheimer Dement"},{"key":"708_CR20","doi-asserted-by":"publisher","unstructured":"Esteve P, Rueda-Carrasco J, Mateo MI, et al. Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer\u2019s disease pathogenesis. Nat Neurosci. \n                  https:\/\/doi.org\/10.1038\/s41593-019-0432-1\n                  \n                .","DOI":"10.1038\/s41593-019-0432-1"},{"key":"708_CR21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.neurobiolaging.2010.03.003","volume":"33","author":"G Cai","year":"2012","unstructured":"Cai G, Atzmon G, Naj AC, et al. Evidence against a role for rare ADAM10 mutations in sporadic Alzheimer disease. Neurobiol Aging. 2012;33:416\u2013417e413. \n                  https:\/\/doi.org\/10.1016\/j.neurobiolaging.2010.03.003\n                  \n                .","journal-title":"Neurobiol Aging"},{"issue":"2","key":"708_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.neuron.2013.08.035","volume":"80","author":"J Suh","year":"2013","unstructured":"Suh J, Choi SH, Romano DM, et al. ADAM10 missense mutations potentiate \u03b2-amyloid accumulation by impairing prodomain chaperone function. Neuron. 2013;80(2):385\u2013401. \n                  https:\/\/doi.org\/10.1016\/j.neuron.2013.08.035\n                  \n                .","journal-title":"Neuron."},{"issue":"2","key":"708_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/mp.2008.84","volume":"15","author":"P Lewczuk","year":"2010","unstructured":"Lewczuk P, Kamrowski-Kruck H, Peters O, et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer\u2019s disease: a multicenter study. Mol Psychiatry. 2010;15(2):138\u201345.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"708_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/BF03402076","volume":"8","author":"F Colciaghi","year":"2002","unstructured":"Colciaghi F, Borroni B, Pastorino L, et al. [alpha]-Secretase ADAM10 as well as [alpha] APPs is reduced in platelets and CSF of Alzheimer disease patients. Mol Med. 2002;8(2):67\u201374. \n                  https:\/\/doi.org\/10.1007\/BF03402076\n                  \n                .","journal-title":"Mol Med"},{"key":"708_CR25","doi-asserted-by":"publisher","unstructured":"Manzine PR, Marcello E, Borroni B, et al. ADAM10 gene expression in the blood cells of Alzheimer\u2019s disease patients and mild cognitive impairment subjects. Biomarkers. 2015. \n                  https:\/\/doi.org\/10.3109\/1354750X.2015.1062554\n                  \n                .","DOI":"10.3109\/1354750X.2015.1062554"},{"issue":"3","key":"708_CR26","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3233\/JAD-150737","volume":"50","author":"F Schuck","year":"2016","unstructured":"Schuck F, Wolf D, Fellgiebel A, Endres K. Increase of \u03b1-Secretase ADAM10 in platelets along cognitively healthy aging. J Alzheimers Dis. 2016;50(3):817\u201326. \n                  https:\/\/doi.org\/10.3233\/JAD-150737\n                  \n                .","journal-title":"J Alzheimers Dis"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00708-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-020-00708-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00708-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T08:02:43Z","timestamp":1604217763000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00708-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,31]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["708"],"URL":"https:\/\/doi.org\/10.1186\/s13195-020-00708-0","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,31]]},"assertion":[{"value":"13 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Study of the family was approved by the Research Ethics Committee at Fundaci\u00f3n Jim\u00e9nez D\u00edaz (Ref. 2014\/ 46), as part of the project \u201cClinical-genetic correlations in inherited dementias\u201d. Informed consent for biological marker and genetic studies was provided by patients or surrogates.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The members of the family described in this study have given written consent for publication of the data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}